cobimetinib
cobimetinib: sourced relationships with 1 company · 6 clinical trials tracked.
cobimetinib evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
How could cobimetinib → EXEL affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| EXELIXIS, INC. (EXEL) | Approved |
Clinical Trial Registry Records (6)
NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer
Primary endpoint: Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)
A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma
Primary endpoint: Proportion of all pharmacodynamic feasibility-evaluable participants within a study arm that have a measurable change in post-treatment tumor biology from baseline
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)
Primary endpoint: Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Primary endpoint: Response Rate
A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Primary endpoint: Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to RECIST v1.1
Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Primary endpoint: Maximum Tolerated Dose (MTD)
Frequently asked questions
Which companies have sourced relationships with cobimetinib?
cobimetinib has dated SEC/FDA relationship records for EXELIXIS, INC..
How many clinical trials involve cobimetinib?
BioSniper tracks 6 clinical trials involving cobimetinib.